HOME >> MEDICINE >> NEWS
Evacuation of elders during disasters to be addressed at GSA's upcoming annual meeting

ng to Complementary and Alternative Medicine (CAM) therapies for a variety of reasons: dissatisfaction with standard medical care, to improve quality-of-life, alleviate chronic pain, and promote general health and longevity. With increased use, further knowledge of the benefits and drawbacks of CAM therapies is becoming crucial. While the field is relatively new and few techniques have been subjected to rigorous studies, there is a growing body of information about CAM utilization and specific applications and techniques. This symposium will provide a brief review of the literature on CAM use in the elderly population and will use a multidisciplinary panel of experts in several CAM modalities to discuss the use and reported benefits of CAM.
Saturday, November 19 at 1:30 p.m.

Transportation Policy for an Aging Society:
Transportation and aging advocates had their concerns heard at three officially designated listening sessions and solutions forums from January through April, 2005 in preparation for the White House Conference on Aging (WHCoA). Policy recommendations were made representing the whole continuum of community mobility from the screening and assessment of critical skills for driving to supplemental transportation programs for elders. Which of the recommendations ultimately made it to the WHCoA delegates? Moreover, which issues were not heard and what work remains for advocates, policy decision-makers, and consumers?
Monday, November 21 at 1:30 p.m.

A Major Trial of Exercise to Prevent Disability: The LIFE Study:
As life expectancy increases, prevention of disability has emerged as a major clinical and public health priority. A critical factor in an older person's ability to function independently is mobility, the ability to move about without assistance. Older people who lose mobility are less likely to remain in the community, have higher rates of morbidity and mortality, have more hospitalizations, a
'"/>

Contact: Todd Kluss
tkluss@geron.org
202-842-1275
The Gerontological Society of America
3-Nov-2005


Page: 1 2 3 4 5

Related medicine news :

1. Evacuation not automatically best for health during chemical incidents
2. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
3. For elders, too few drugs are as much a risk as too many
4. Orlando press briefing: Budget cut puts elders health at risk
5. Michigan-CDC study supports value of social restrictions during influenza pandemics
6. Are parking garages safe during hurricanes?
7. Smoking may interfere with alcoholics neurocognitive recovery during abstinence
8. Genetic variations may predispose some men to suicidal thoughts during treatment for depression
9. Study questions risks of anti-bleeding drug during heart surgery
10. Pfizer Onocology press briefing scheduled during ASCO 2007 Annual Meeting
11. UW study to clarify safety, effectiveness of hormone therapy during menopause

Post Your Comments:
(Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
(Date:3/30/2015)... Linda, CA (PRWEB) March 30, 2015 ... challenging due to the use of cellular models that ... not the entirety of the disease. , A ... human cells to precise specifications has created ... to develop environmentally and genetically driven in vitro models ...
(Date:3/29/2015)... Calif. (PRWEB) March 30, 2015 Over ... menopause-related symptoms tied to undiagnosed autoimmune, thyroid, or hormone ... thyroid disorders, has personally treated hundreds of patients dealing ... are unaware of the treatment options for their ailments. ... offers solutions to women living with fatigue, brain fog, ...
(Date:3/29/2015)... Telerad RxDx Multispecialty Healthcare Center, ... Accreditation on 11th January 2015. The accreditation from ... Providers) comes as a true recognition of the ... RxDx., With Telerad RxDx being the first healthcare ... marks a major achievement and a significant step ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
Breaking Medicine News(10 mins):Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:How to Turn Mid-life into the Good Life 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences International, ... primary efficacy endpoint in the Phase 3 clinical ... for the treatment of painful diabetic neuropathy did ... showed statistically significant improvement over placebo.  In addition, ... observed.  The results of this trial provide data ...
(Date:3/29/2015)... 2015  Three-month paliperidone palmitate, an investigational atypical ... placebo in patients with schizophrenia, according to a ... in the Journal of the American ... Results of the study served as the basis ... for three-month paliperidone palmitate injection to treat schizophrenia ...
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
Cached News: